These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26668126)

  • 21. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
    Krejčík Z; Beličková M; Hruštincová A; Kléma J; Zemanová Z; Michalová K; Čermák J; Jonášová A; Dostálová Merkerová M
    Cancer Genet; 2015 Apr; 208(4):156-61. PubMed ID: 25883014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
    Jädersten M; Karsan A
    Haematologica; 2011 Feb; 96(2):177-80. PubMed ID: 21282717
    [No Abstract]   [Full Text] [Related]  

  • 24. Lenalidomide in del 5q MDS: responses and side effects revisited.
    Tiu RV; Sekeres MA
    Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
    [No Abstract]   [Full Text] [Related]  

  • 25. Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
    Vigna E; Recchia AG; Cuzzola M; Morabito L; Gentile M; Morabito F
    Leuk Lymphoma; 2014 Jun; 55(6):1408-9. PubMed ID: 23952245
    [No Abstract]   [Full Text] [Related]  

  • 26. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).
    Sekeres MA; Swern AS; Fenaux P; Greenberg PL; Sanz GF; Bennett JM; Dreyfus F; List AF; Li JS; Sugrue MM
    Blood Cancer J; 2014 Aug; 4(8):e242. PubMed ID: 25171203
    [No Abstract]   [Full Text] [Related]  

  • 27. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
    Mohr B; Oelschlaegel U; Thiede C; Stewart MM; Ehninger G; Platzbecker U
    Haematologica; 2009 Mar; 94(3):430-1. PubMed ID: 19181778
    [No Abstract]   [Full Text] [Related]  

  • 28. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
    Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
    Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
    [No Abstract]   [Full Text] [Related]  

  • 29. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 30. Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
    Oelschlaegel U; Westers TM; Mohr B; Kramer M; Parmentier S; Sockel K; Thiede C; Bornhäuser M; Ehninger G; van de Loosdrecht AA; Platzbecker U
    Haematologica; 2015 Mar; 100(3):e93-6. PubMed ID: 25425689
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment.
    Knop S; Einsele H; Bargou R; Cosgrove D; List A
    Leuk Lymphoma; 2008 Feb; 49(2):346-9. PubMed ID: 18231924
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
    Abouyahya I; Alhan C; Westers TM; te Boekhorst PA; Kappers-Klunne MC; Coenen JL; Heyning FH; Huls GA; de Wolf JT; Imholz AL; Koene HR; Veth G; de Kruijf EJ; Muus P; Planken EV; Segeren CM; Vasmel WL; van der Velden AM; Velders GA; Koedam J; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Lymphoma; 2013 Apr; 54(4):874-7. PubMed ID: 22971215
    [No Abstract]   [Full Text] [Related]  

  • 33. Where Does Lenalidomide Fit in Non-del(5q) MDS?
    Giagounidis A
    Curr Hematol Malig Rep; 2015 Sep; 10(3):303-8. PubMed ID: 26169489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 35. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
    Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
    Mortensen TB; Frederiksen H; Marcher CW; Preiss B
    BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28052942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
    Jädersten M
    Haematologica; 2010 Mar; 95(3):348-51. PubMed ID: 20207839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.